Trial Profile
Phase II evaluation of weekly docetaxel in combination with weekly carboplatin in the treatment of recurrent epithelial ovarian carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2019
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Docetaxel (Primary)
- Indications Carcinoma; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Dec 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 07 Nov 2005 New trial record.